Industry: Cancer pharmaceuticals
Vesta Biomedical’s vesicular stomatitis virus drug (VSV-S) is a potent anti-cancer virus.
Animal trials using cancers genetically identical (syngeneic) to those found in humans found that an intratumoral injection of VSV-S reduced tumors by up to 85% and enhanced cellular immune responses.
In accordance with expert feedback, Vesta has tested the effectiveness of the drug in treating pancreatic, breast, and lung cancers. At this stage, VSV-S has not induced severe adverse effects even after a large dose, with no observed cytotoxicity.
VSV-S could be administered either directly into the tumor or intravenously, and the comparative effectiveness of administrations will be studied.